OKYO Pharma Ltd ADR Total Liabilities
OKYO Pharma Ltd ADR total liabilities. Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has total liabilities worth $8.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of OKYO Pharma Ltd ADR to evaluate the company's liquid asset resilience ratio.
Total Liabilities of OKYO Pharma Ltd ADR (2008–2026)
Total liabilities of OKYO Pharma Ltd ADR from 2008 to 2026. This chart illustrates how OKYO Pharma Ltd ADR's total liabilities have evolved over time, based on quarterly financial data.
OKYO Pharma Ltd ADR Competitors by Total Liabilities
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunview Group Bhd
KLSE:0262
|
Malaysia | RM351.45 Million |
|
Euro India Fresh Foods Limited
NSE:EIFFL
|
India | Rs-770.60 Million |
|
Soke Degirmencilik AS
IS:SOKE
|
Turkey | TL1.42 Billion |
|
Ta Yih Industrial Co Ltd
TW:1521
|
Taiwan | NT$1.20 Billion |
|
GreenMobility A/S
CO:GREENM
|
Denmark | Dkr139.33 Million |
|
OFCO Industrial
TWO:5011
|
Taiwan | NT$2.96 Billion |
|
Gipta Ofis Kirtasiye ve Promosyon Ãrünleri Imalat Sanayi A.S.
IS:GIPTA
|
Turkey | TL692.51 Million |
|
Jia Wei Lifestyle Inc
TW:3557
|
Taiwan | NT$4.26 Billion |
Liability Composition Analysis (2008–2026)
This chart breaks down OKYO Pharma Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OKYO Pharma Ltd ADR asset portfolio.
Liquidity & Leverage Metrics
OKYO Pharma Ltd ADR Total Liabilities Ratios Explained
OKYO Pharma Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OKYO Pharma Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual total liabilities of OKYO Pharma Ltd ADR from 2008 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $8.64 Million | -6.35% |
| 2025-03-31 | $9.23 Million | +24.34% |
| 2024-03-31 | $7.42 Million | +2.26% |
| 2023-03-31 | $7.26 Million | +436.30% |
| 2022-03-31 | $1.35 Million | -23.63% |
| 2021-03-31 | $1.77 Million | +140.36% |
| 2020-03-31 | $737.20K | +72.76% |
| 2019-03-31 | $426.72K | +368.62% |
| 2018-03-31 | $91.06K | -64.81% |
| 2017-03-31 | $258.76K | +42.69% |
| 2016-03-31 | $181.34K | +20.04% |
| 2015-03-31 | $151.07K | -39.07% |
| 2014-03-31 | $247.95K | +35.25% |
| 2013-03-31 | $183.32K | -77.99% |
| 2012-03-31 | $832.89K | +957.75% |
| 2011-03-31 | $78.74K | -1.42% |
| 2010-03-31 | $79.87K | -7.08% |
| 2009-03-31 | $85.96K | -40.66% |
| 2008-03-31 | $144.86K | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more